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Abstract Group A Streptococcus (GAS) is a human patho-
gen causing a wide range ofmild to severe and life-threatening
diseases. The GAS M1 protein is a major virulence factor
promoting GAS invasiveness and resistance to host innate
immune clearance. M1 displays an irregular coiled-coil struc-
ture, including the B-repeats that bind fibrinogen. Previously,
we found that B-repeat stabilisation generates an idealised
version of M1 (M1*) characterised by decreased fibrinogen
binding in vitro. To extend these findings based on a soluble
truncated version of M1, we now studied the importance of
the B-repeat coiled-coil irregularities in full length M1 and
M1* expressed in live GAS and tested whether the modula-
tion of M1–fibrinogen interactions would open up novel
therapeutic approaches. We found that altering either the M1
structure on the GAS cell surface or removing its target host
protein fibrinogen blunted GAS virulence. GAS expressing
M1* showed an impaired ability to adhere to and to invade
human endothelial cells, was more readily killed by whole
blood or neutrophils and most importantly was less virulent in
a murine necrotising fasciitis model. M1-mediated virulence
of wild-type GAS was strictly dependent on the presence and
concentration of fibrinogen complementing our finding that
M1–fibrinogen interactions are crucial for GAS virulence.
Consistently blocking M1–fibrinogen interactions by frag-
ment D reduced GAS virulence in vitro and in vivo. This
supports our conclusion that M1–fibrinogen interactions are
crucial for GAS virulence and that interference may open up
novel complementary treatment options for GAS infections
caused by the leading invasive GAS strain M1.
Keywords Group A Streptococcus . M protein .
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Introduction
The Gram-positive bacterium group A Streptococcus (GAS)
is a leading human pathogen. It causes a substantial disease
burden ranging from mild to life-threatening conditions. An-
nually worldwide, GAS is responsible for >700 million cases
of pharyngitis or skin infection and >650,000 invasive in-
fections including necrotising fasciitis (NF) and streptococcal
toxic shock syndrome (STSS) [1]. The increasing incidence of
severe GAS diseases in recent decades is in large part attrib-
utable to the emergence of a globally disseminated clone of
the M1T1 serotype [2, 3]. M1T1 strains are the most common
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cause of GAS pharyngitis and are strongly overrepresented in
severe cases, such as NF and STSS [4].
The M1 protein is a major surface protein and virulence
factor expressed by GAS M1T1. M1 contributes to GAS
adhesion to host cells [5, 6], provokes inflammation by
stimulating macrophages or neutrophils to release cytokines
and heparin-binding protein [7–10], and promotes GAS
intracellular survival [11]. M1 binds host fibrinogen [12],
which can camouflage opsonic targets on the GAS surface
t o p romo t e eva s i on o f comp l emen t -med i a t e d
opsonophagocytic killing [13, 14]. Complexes composed
of truncated M1 protein shed from the GAS surface and
fibrinogen assemble into M1–fibrinogen networks [9], key
factors in provoking excessive neutrophil activation and
STSS symptoms [10].
Nonideal coiled-coil residues give rise to specific irregu-
larities in the M1 protein’s dimeric α-helical coiled-coil struc-
ture [7], including the B-repeats which are essential for
interactions with fibrinogen. To validate the importance of
these irregularities or ‘imperfections” in the M1 coiled-coil
structure to GAS disease pathogenesis, we previously re-
placed the amino acids alanine responsible for the irregulari-
ties of the coiled-coil structure in the B-region to generate an
idealised version of the M1 protein (M1*) (Fig. S1a in the
Electronic supplementary material (ESM)) [7]. Because a few
of the mutated residues were found to make contact to fibrin-
ogen, we then created a second mutant, M1*-R, that contains
all the wild-type (WT) fibrinogen-binding residues but is
stabilised in register 1. This mutant was as deficient as M1*
in binding fibrinogen, indicating that it was the stabilisation of
the coiled-coil register M1* rather than the loss of specific
amino acids that resulted in poor fibrinogen binding [9]. The
recombinant idealised, truncated M1* protein fragment in its
soluble form showed greater protein stability but diminished
binding to fibrinogen in vitro suggesting that the irregularity
of the coiled-coil structure in the B-repeats could contribute to
GAS virulence [7]. In the present study, we have now
engineered the full length and membrane anchored idealised
M1* to be expressed in GASM1T1 by precise in frame allelic
replacement of the emm1 gene. This mutant GAS strain GAS
M1* allowed to assess for the first time the role of the irregular
coiled-coil structure in the context of the intact living organ-
ism, using tissue culture and small animal models of infection
and to test if interference with M1–fibrinogen interaction
could open up novel therapeutic approaches.
Materials and methods
Ethics statement
Animal studies C57Bl/6 WT mice were handled in strict ac-
cordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol 140/2011 was approved by the Institution-
al Animal Care and Use Committee of the University of Zurich.
Blood was drawn from healthy volunteers in strict accor-
dance with the institutional guidelines according to Decla-
ration of Helsinki principles. The protocol 2010-0126/0 was
approved by the Institutional Review Board of the Univer-
sity of Zurich. Written informed consent was received from
all participants.
Bacterial strains
The GAS strain 5448, a well-characterised M1T1 clinical
isolate from a patient with necrotising fasciitis and toxic
shock syndrome [15], the M protein knockout (GASΔM1)
[16], and the GASM1* strains in the M1T1 5448 back-
ground were propagated in Todd–Hewitt broth (THB;
Difco, BD Diagnostics) or THB agar plates.
Engineering of GAS strain expressing idealised M1
The sequence encoding the N-terminal sequence of M1* (1–
345aa) was excised from the pET28b vector [7] using the
restriction enzymes XbaI/HindIII (NEB). The sequence
encoding the C-terminal sequence of M1 protein (346–485aa)
was excised from the pCR2.1 TOPO vector [16] using restric-
tion enzymes HindIII/KpnI (NEB). These two fragments were
ligated overnight and the ligated fragment, representing the
whole emm1* gene, was cloned into the pCR2.1 TOPO vector
(Invitrogen) at XbaI and KpnI. Successful cloning and creation
of the pCR2.1 TOPO-emm1* vector was confirmed by se-
quencing. The CDS encoding emm1* was then sub-cloned into
the temperature sensitive vector pHY304 at EcoRI and BamHI
to give rise to the pemm1* vector. Electrocompetent GAS M1
5448 cells were transformed with the pemm1* vector; double
crossover events were screened by PCR followed by restriction
digest using PVUII, only present in the emm1* gene. The
correct genomic insertion and sequence were verified and
confirmed by sequencing.
M protein surface detection by western blot
and flowcytometry
GAS strains were grown to OD600=0.4 in THB. Western
blot was carried out as previously described [17]. Pellets
from 1-ml overnight cultures of GAS strains were heated
at 90 °C for 10 min in Laemmli buffer followed by
separation by SDS page and transfer to PVDF mem-
branes (Millipore). After blocking, the membranes were
incubated with a polyclonal rabbit α-M1 antibody
followed by incubation with an α-rabbit antibody
(Invitrogen). Immunoreactive bands were detected using
the Super Signal West Pico chemoluminescent substrate
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(Pierce). For flow cytometery, 1 ml of the bacterial
culture was pelleted, washed, and resuspended in PBS+
10 % BSA for blocking. After washing, the pellet was
incubated with the rabbit polyclonal antibody against M1
protein, then resuspended in goat anti-rabbit (FAB) Alexa
488 (Invitrogen), washed and finally resuspended in PBS
for FACS analysis.
Fibrinogen-binding measurements by FACS
Fibrinogen (CSD Behring) was labelled with FITC using the
FluoReporterR Protein Labeling Kit (Invitrogen) and added
to GAS strains grown to OD600=0.4 in THB, samples were
incubated for 30 min. To measure fibrinogen binding to
GAS in the presence of fragment D, fragment D (as prepared
in [7]) was added at a concentration of 500 μg/ml together
with 50 μg/ml FITC-labelled fibrinogen before FACS anal-
ysis (FACSScan, BectonDickinson).
Adherence and invasion assay
Adherence and invasion assays were performed as previ-
ously described [18] using the EA.hy926 endothelial cell
line [19] grown to confluence in DMEM+10 % FCS and
split into 24-well plates and cultivated in DMEM+0.4 %
BSA. GAS strains (OD600 0.4) were resuspended in
DMEM+0.4 % BSA and added to the endothelial cells at
a MOI of 1 for adherence or MOI of 10 for invasion assays.
For the fragment D competition assay, either 50 μg/ml
fibrinogen (CSL Behring) or 50 μg/ml fibrinogen plus
500 μg/ml fragment D were added and the bacteria were
incubated for 30 minutes at 37 °C. The fibrinogen or
fibrinogen plus fragment D coated bacteria were used for
adherence and invasion assays as described above. To
visualise and quantify the adhesion by fluorescence mi-
croscopy, EA.hy926 cells were grown on bovine
fibronectin-coated (Invitrogen) glass coverslips (Thermo
Scientific) in a 24-well plate and challenged with the
GAS strains at a MOI of 1. After fixation with 4 %
paraformaldehyde and co-incubation with either a poly-
clonal rabbit anti-GAS or isotype control (R&D Systems)
Alexa Fluor® 488F(ab′)2 anti-rabbit IgG (Invitrogen)
was used as secondary antibody. DAPI dihydrochloride
(Sigma) was then added and glass slides mounted with
ProlongGold antifade reagent (Invitrogen). Fluorescence
microscopy images were taken using an Olympus
inverted microscope IX71 equipped with a mercury burn-
er U-RFL-T as light source, an Olympus XM10 digital
camera and a 10×/0.30 Ph1 UPlanFLN Olympus objec-
tive at calibrated magnifications. Images were taken and
identically processed using the CellF imaging software
(version 3.2) from Olympus. The fluorescence signal for
one field is derived from the sum of grey value intensity
per field. The average background signal was calculated
as the mean of ten images of the isotype control. The
corrected fluorescence intensity of a field was calculated
by subtraction of the average background signal from the
fluorescence signal of the field. Means of corrected in-
tensity values of at least five pictures per slide,
performed in triplicate, were calculated. Microscope set-
tings were kept constant during image acquisition.
Whole blood and neutrophil killing assays
Whole blood killing assay was performed as previously
described with some minor modifications [20]. Ancrod
(Serva electrophoresis) was added at a final concentration
of 0.1 U/ml to whole blood and the blood with or without
Ancrod was incubated for 30 min rotating at 37 °C for
defibrinogenisation.
Neutrophil killing assays were performed as previously
described with some minor modifications [21]. Human neu-
trophils were challenged with GAS strains that had been
pre-incubated with either 100 μg/ml fibrinogen or 500 μg/ml
fragment D alone or with both 50 μg/ml fibrinogen and
500 μg/ml fragment D at an MOI of 1. Neither fibrinogen
nor fragment D was added in control samples. To assess
extracellular killing, neutrophils were preincubated with
1 μM cytochalasin D (Sigma) for 30 min at 37 °C.
Murine infection model
GAS was injected subcutaneously into the flanks of 10-
to12-week-old C57Bl/6 WT mice [21] purchased from
Janvier, France: on the one side GAS M1 on the other side
the GAS M1* was injected. Skin lesion sizes were moni-
tored daily for 4 days, then the mice were sacrificed and the
bacteria present in the skin lesions enumerated. For the
fragment D competition assay, either fragment D at a final
concentration of 1.5 mg/ml or PBS as control was added to
GAS M1. GAS M1 with fragment D was injected on one
side and on the other side GAS M1 without fragment D.
Lesions sizes were assessed as described above.
Statistics
Data were analysed and edited using the SPSS (SPSS 11.5
Inc., Chicago, Illinois), the NCSS (Kaysville, Utah), and
Graphpad prism 5 software (Graphpad Software Inc, La
Jolla, California) packages. Two-sample two-tailed homo-
scedastic t tests or a nonparametric Mann–Whitney U test
were used to calculate the indicated p values. Statistics show
p values compared with WT in the same group unless
indicated by brackets. In vivo data were analysed by two-
tailed Wilcoxon signed-rank test for paired samples.
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Results
Construction and characterisation of a GAS M1* strain
To explore the effects of the full length and cell surface
expressed idealised α-helical coiled-coil protein in the patho-
genesis of GAS, the WTM1 protein gene emm1was replaced
by the emm1* mutated gene (Fig. S1b in the ESM) by precise
allelic replacement. The integrity of this mutation was con-
firmed by chromosomal DNA sequencing. Expression of
M1* and its localisation on the bacterial surface were analysed
by western blot and FACS (Fig.1a, b). No difference in
bacterial growth between GAS expressing M1 and M1* was
observed (Fig. S2a in the ESM). To control that only M
protein was affected and no other GAS virulence factors
influencing pathogenicity, the activity levels of the GAS neu-
trophil resistance factors streptolysin O (SLO) and DNase
(Sda1) were assessed and found to be comparable (Fig. S2b,
c in the ESM). SLO induces apoptosis in macrophages [22]
and DNase degrades NETs [23, 24]which both facilitate GAS
to evade the innate immune system.
Reduced fibrinogen binding by GAS M1* resulting
in reduced adherence to and invasion of endothelial cells
in the presence of fibrinogen
M1 proteins expressed on GAS surface or shed into the super-
natant have both been shown to bind host fibrinogen, allowing
bacterial camouflage and blunting of the host’s innate immune
clearance mechanisms [10]. We thus tested whether the
idealisation of the B-repeats in the full length cell surface
expressed GAS M1* would result in reduced fibrinogen bind-
ing to GAS. The capacity of the GAS strains to bind FITC-
labelled fibrinogen was quantified by FACS. We found that
GAS M1* bound FITC-fibrinogen less readily than GAS M1
(Fig.1c, d). The similar M1 protein expression levels found by
western blotting and flow cytometery (Fig.1a, b) make it
unlikely that the reduced fibrinogen binding could be caused
by decreased surface expression of M1 variants. Lack of M1
(GASΔM1) resulted in failure to bind fibrinogen (Fig. 1c, d).
Endothelial cells have been shown to interact with fibrin-
ogen [25]. We thus explored whether fibrinogen coating of
GAS would facilitate adherence to and invasion of endothe-
lial cells line EA.hy926. GAS M1 strain displayed signifi-
cantly higher adherence to and invasion of EA.hy926 cells
compared with GAS M1* at ≥10 μg/ml (Fig. 2a, b). These
quantitative observations were further corroborated by fluo-
rescence microscopy (Fig. 2c, d).
Reduced fibrinogen binding lowers the ability of GAS M1*
to circumvent host innate immune killing
We next examined whether the difference in fibrinogen
binding between GAS M1 and GAS M1* affected the
ability of host innate immune cells to clear the pathogen.
GAS killing assays were performed using human whole
blood derived from healthy volunteers. The superior ability
of GAS M1 to bind fibrinogen correlated with enhanced
Fig. 1 Characterisation of GAS
M1*. Expression of WT M1
(GAS M1) and idealised M1
protein (GAS M1*) in GAS
was analysed by western blot
(a) and FACS (b). c Binding of
FITC-labeled fibrinogen (Fg) to
the various GAS strains as
analysed by FACS analysis
with quantitative analyses given
in (d). Representative
experiments out of three
independent repeats (a–c),
pooled from three independent
experiments (d)
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survival compared with both the isogenic ΔM1 and M1*
mutant strains (Fig. 3a). To test if this enhanced survival was
dependent on the presence of fibrinogen, whole blood was
fibrinogen depleted by adding the snake venom Ancrod
[26]. Fibrinogen depletion rendered GAS M1 as avirulent
as the isogenic ΔM1 and M1* strains (Fig. 3a). Since
neutrophils are abundant in the blood and are the first
phagocytes to respond to a bacterial infection, we performed
a GAS neutrophil killing assay. In this assay, addition of
fibrinogen exaggerated the difference in survival between
GAS M1 and M1* strains; whereas in the absence of fibrin-
ogen, no difference was observed between these two groups
(Fig. 3b). The survival of the ΔM1 strain was significantly
reduced both in the presence or absence of fibrinogen as
expected given the importance of M1 protein for intracellu-
lar survival of GAS in neutrophils [11]. In the next step we
examined neutrophil extracellular killing employing cyto-
chalasin D to block phagocytosis. The pattern of GAS
survival, GAS M1>GAS M1*>GAS ΔM1 in the presence
of fibrinogen further established the importance of
fibrinogen binding for GAS resistance to extracellular neu-
trophil killing in NETs (Fig. 3c). The enhanced NETs killing
of the GAS M1 strain reflected our previous finding that
GAS M1 protein is necessary to promote bacterial resistance
to killing in NETs and that it contributes to resistance to the
human cathelicidin antimicrobial peptide LL-37 [16].
The M1 protein diminishes extracellular GAS suscepti-
bility to the antimicrobial peptide cathelicidin, which is a
key component of neutrophils extracellular traps (NETs)
[16]. Therefore we examined GAS neutrophil extracellular
killing by NETs. To examine the survival of GAS exposed
to NETs, neutrophils were pre-stimulated with phorbol
myristate acetate (PMA) which activates the protein kinase
C [27, 28] thereby triggering nearly 100 % of the neutro-
phils to produce NETs [29]. In the absence of fibrinogen, no
difference in killing within NETs was observed between
GAS M1 and M1*. However, when the GAS strains were
pre-incubated with fibrinogen, GAS M1 was more resistant
to NET-mediated killing compared with GAS M1*. In con-
trast, the GAS strains GAS M1* and ΔM1 which did not
Fig. 2 Correlation of fibrinogen M1 protein binding with GAS adhe-
sion to and invasion of endothelial cells. a–d Human endothelial cells
(EA.hy926) were challenged with GAS strains to assess the ability of
GAS to a adhere to and b to invade host cells. GAS strains were pre-
incubated with given concentrations of fibrinogen. Increasing fibrino-
gen concentrations boosted adherence and invasion only in the M1
protein-expressing GAS. c Representative bright field and fluorescence
microscopy images showing GAS (green) adhering to EA.hy926cells.
d Quantification of detected fluorescence signal in the absence (con-
trol) or presence of fibrinogen (100 μg/ml). Adherence of GAS ΔM1
was independent of fibrinogen, whereas fibrinogen improved adher-
ence of GAS M1 and to a lesser extent of GAS M1*. a, b Data were
pooled from three independent experiments. Mean±SEM; *p<0.05;
**p<0.01. d Experiments were performed in triplicate with two inde-
pendent repeats, presented mean±SD; **p<0.01; arbitrary units; scale
bar represents 100 μm
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bind fibrinogen as well were susceptible to NET-mediated
killing independent of fibrinogen (Fig. 3d).
GAS expressing M1* displays reduced virulence
in a murine skin infection model
To extend our in vitro findings to an in vivo model and to
directly compare the virulence of GAS M1 and M1* strains
C57Bl/6 WT mice were infected subcutaneously with GAS
M1 and M1*. The resultant lesion sizes at the site of infec-
tion were measured over time and bacterial counts in mice
skin homogenates were assessed. The lesion sizes after
infection with the GAS M1* strain were significantly small-
er than the lesion size caused by GAS M1 (Fig. 3e). In
addition, the GAS M1* strain had significantly diminished
in vivo survival at the site of infection compared with the
GAS M1 strain, as calculated by the number of surviving
bacteria recovered from the skin homogenates (Fig. 3f).
Interference of fibrinogen fragment D with GAS virulence
in vitro and in vivo
Fibrinogen fragment D is generated by degradation of fi-
brinogen by plasmin and was shown to interact with the
GAS M1 protein [9] and might also interfere with fibrin
formation. We hypothesised that fragment D could interfere
with the formation of M1–fibrinogen networks on the GAS
surface, ultimately resulting in fewer and weaker interac-
tions of GAS with host cells. Indeed, FACS analysis showed
that fibrinogen fragment D hinders fibrinogen binding to
GAS M1 (Fig. 4a). Coating bacteria with fragment D
alone did not have an effect on neutrophil killing
(Fig. 4b) while in the presence of both fragment D
and intact fibrinogen, fragment D partially but signifi-
cantly inhibited neutrophil killing (Fig. 4b) as well as
adherence to and invasion of endothelial cells by GAS
(Fig. 4c, d). When fragment D was added to GAS M1
Fig. 3 Fibrinogen binding
hinders GAS clearance by the
host innate immune system and
enhances GAS virulence. a
Resistance to whole blood killing
in the absence (Ancrod+) or
presence (Ancrod−) of
endogenous fibrinogen. b
Resistance to neutrophil killing in
the absence (minus sign) or
presence (plus sign) of exogenous
fibrinogen (Fg). c Extracellular
killing by neutrophils in which
phagocytosis was blocked
(cytochalasin D) in the absence
(minus sign) or presence (plus
sign) of fibrinogen. d NETs
formation by neutrophils was
induced by addition of PMA
before the survival of GAS was
examined in the absence (minus
sign) or presence (plus sign) of
fibrinogen. e, f C57Bl/6 mice
were infected subcutaneously
withGASM1 andGASM1* into
the opposite flanks. eTime course
of skin lesions size after GASM1
and GAS M1* infection. f At
day 4, the infected skin of the
animals shown in (e) was
harvested and homogenised to
enumerate surviving bacteria. a–
d Data were pooled from three
independent experiments done in
triplicate, mean±SEM; *p<0.05;
**p<0.01; ***p<0.001. e, fData
were pooled from two
independent experiments,
N=11; *p<0.05
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before subcutaneous injection in our in vivo model, the
bacteria were cleared significantly more efficiently
(Fig. 4f) corroborating with our in vitro findings. Con-
sistent with abolishing GAS virulence, fragment D led
to a trend (p=0.15) for smaller skin lesions formed by
GAS M1 (Fig. 4e).
Discussion
Using precise allelic replacement technology we engineered
a modified GAS M1T1 strain that expresses the idealised
M1* protein characterised by a more stable α-helical coiled-
coil structure. This novel GAS M1* strain allowed to di-
rectly study the importance of M1–fibrinogen interaction for
GAS virulence. We show that bacterial virulence depends
on both the functionality of the GAS virulence factor M1 as
well as on the presence of the host protein fibrinogen.
Our tool set consisting of GAS either expressing M1,
expressing a fibrinogen-binding-deficient M1* or the knock
out strain in conjunction with availability of the host protein
fibrinogen (either present in the serum or exogenously
added) or its depletion (using either washed host cells or
by adding Ancrod) allowed for the first time to fulfil an
adapted molecular Koch’s postulate examining the role of
M1 protein–fibrinogen interaction for GAS adherence and
invasion, resistance to whole blood and neutrophil killing as
well as for virulence in a murine necrotising fasciitis model.
Blocking the fibrinogen–M1 protein interaction with frag-
ment D adds novel treatment concepts.
In addition to allowing to directly and specifically ana-
lyse the importance of M1–fibrinogen interaction for GAS
virulence in vitro and in vivo, our novel tools helped to
overcome some limitations of previous models using M
protein-deficient GAS strains in which the GAS surface
may be fundamentally altered due to the absence of this
very abundant surface protein. Furthermore, appropriate
expression of the modified protein and unspecific effects
are major concerns in engineered pathogens: using two
independent techniques, western blot and flow cytometry,
Fig. 4 Interference of fragment
D with fibrinogen binding
blunts GAS virulence in vitro
and in vivo. a GAS surface
binding of FITC-labeled
fibrinogen (Fg) following
incubation of GAS M1 with or
without the competitor
fragment D (FgD; 500 μg/ml)
analysed by FACS. b GAS M1
was pre-incubated with either
50 μg/ml fibrinogen, 500 μg/ml
fragment D, or both before
neutrophil challenge and
analysis of survival. c Adhesion
to and d invasion of EA.hy926
cells by GAS M1 (control),
GAS M1 coated with 50 μg/ml
Fg, or GAS M1 coated with
50 μg/ml fibrinogen plus
500 μg/ml fragment D
(Fg+FgD). e, f C57Bl/6 mice
were infected subcutaneously
with GAS WT coated (one
flank) or not (other flank) with
FgD, and the development of
lesions over time and amount of
surviving GAS at day 4 was
analysed. a, d Representative
graphs from three independent
experiments. b, c Data were
pooled from three independent
experiments. b–d Data shown
as mean±SEM. e, f Data were
pooled from two independent
experiments, N=12; *p<0.05;
**p<0.01; ***p<0.001
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we showed comparable cell surface protein expression after
successful allelic replacement of emm1 by emm1* and ex-
cluded differences in growth and expression of two major
GAS virulence factors slo and sda1.
Our novel tools illustrate how tightly entwined host and
pathogens are and that both the pathogen as well as the host
contributes to virulence. We found that GAS virulence is
blunted when either (1) fibrinogen is depleted or when
fragment D competes for M1–fibrinogen interaction as well
as when (2) the M protein is altered (GAS M1*) or absent
(GASΔM1). In contrast to GAS M1T1 which harbours a
single emm gene other less common GAS serotypes express
additional fibrinogen-binding proteins on their cell surface
such as the serum opacity factor SOF and the M protein-like
surface proteins. Thus loss of M protein-fibrinogen interac-
tion in non-M1 GAS strains could, at least in part, be
compensated and our findings might thus not be represen-
tative for all pathogenic GAS strains.
Fibrinogen has been shown to facilitate leucocytes endo-
thelial cells interactions [25]. We now provide novel evi-
dence that fibrinogen also supports bacterial-endothelial
interactions in the presence of the functional GAS fibrino-
gen receptor M1. Fibrinogen coating GAS facilitated adher-
ence to and invasion of endothelial cells, both factors
important for pathogenicity of invasive infections [30, 31].
Fibrinogen at concentrations as low as 10 μg/ml enhanced
GAS virulence when the fibrinogen-binding M1 protein was
available. In addition to blood, the extravascular compart-
ment also contains high levels of fibrinogen, in particular
during inflammation, further supporting M1–fibrinogen in-
teraction and thus GAS virulence.
Earlier studies described M1–fibrinogen binding as a
mechanism allowing GAS bacterial camouflage and
blunting of the host’s innate immune clearance mechanisms
[10]. Our studies of bacterial survival in whole blood or in
presence of neutrophil confirm these conclusions and further
illustrate that the host protein fibrinogen is required and has
to interact with the bacterial virulence factor M protein to
result in virulence. Our observations that M1–fibrinogen
interactions help GAS to resist NET-mediated neutrophil
killing are consistent with previous work showing NETs
support bacterial clearance from blood [32] and that M1
protein diminishes extracellular GAS susceptibility to the
antimicrobial peptide cathelicidin, a key component of NET
[16]. These findings underscore the importance of the native
M1 protein structure both for fibrinogen binding and resis-
tance of GAS to the innate immune response.
Combining knowledge on how M1–fibrinogen bind [9]
with understanding the relevance of the M1–fibrinogen
interaction we tested fragment D known to bind M1 protein
but able neither to polymerise nor to mediate adherence to
mammalian fibrinogen receptors as a potential therapeutic.
As proof of principle we found that fragment D blunts GAS
virulence in vitro and had therapeutic effects in an in vivo
necrotising fasciitis model. It however remains to be clari-
fied whether fibrinogen receptors other than M1 bind frag-
ment D [33] not only efficiently but potentially even better
than fibrinogen [34].
To conclude, we showed that GAS expressingM1* showed
impaired fibrinogen binding resulting in less invasiveness and
reduced resistance towards cell and NET-mediated host killing
which translated into reduced virulence in a murine
necrotising fasciitis model. We further provide novel evidence
that interfering with the M1–fibrinogen interaction by adding
the exogenous competitor fragment D reduced pathogenicity
of GAS M1T1 indicating that competition with or partial
blockage of fibrinogen may open up complementary treatment
options for life-threatening invasive GAS infections.
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